Cargando…

The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers

Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis an...

Descripción completa

Detalles Bibliográficos
Autores principales: OJI, YUSUKE, TATSUMI, NAOYA, FUKUDA, MARI, NAKATSUKA, SHIN-ICHI, AOYAGI, SAYAKA, HIRATA, ERIKA, NANCHI, ISAMU, FUJIKI, FUMIHIRO, NAKAJIMA, HIROKO, YAMAMOTO, YUMIKO, SHIBATA, SYOHEI, NAKAMURA, MICHIYO, HASEGAWA, KANA, TAKAGI, SAYAKA, FUKUDA, IKUYO, HOSHIKAWA, TOMOKO, MURAKAMI, YUI, MORI, MASAHIDE, INOUE, MASAYOSHI, NAKA, TETSUJI, TOMONAGA, TAKESHI, SHIMIZU, YOSHIFUMI, NAKAGAWA, MASASHI, HASEGAWA, JUNICHI, NEZU, RIICHIRO, INOHARA, HIDENORI, IZUMOTO, SHUICHI, NONOMURA, NORIO, YOSHIMINE, TOSHIKI, OKUMURA, MEINOSHIN, MORII, EIICHI, MAEDA, HAJIME, NISHIDA, SUMIYUKI, HOSEN, NAOKI, TSUBOI, AKIHIRO, OKA, YOSHIHIRO, SUGIYAMA, HARUO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027928/
https://www.ncbi.nlm.nih.gov/pubmed/24589652
http://dx.doi.org/10.3892/ijo.2014.2318
_version_ 1782317015742021632
author OJI, YUSUKE
TATSUMI, NAOYA
FUKUDA, MARI
NAKATSUKA, SHIN-ICHI
AOYAGI, SAYAKA
HIRATA, ERIKA
NANCHI, ISAMU
FUJIKI, FUMIHIRO
NAKAJIMA, HIROKO
YAMAMOTO, YUMIKO
SHIBATA, SYOHEI
NAKAMURA, MICHIYO
HASEGAWA, KANA
TAKAGI, SAYAKA
FUKUDA, IKUYO
HOSHIKAWA, TOMOKO
MURAKAMI, YUI
MORI, MASAHIDE
INOUE, MASAYOSHI
NAKA, TETSUJI
TOMONAGA, TAKESHI
SHIMIZU, YOSHIFUMI
NAKAGAWA, MASASHI
HASEGAWA, JUNICHI
NEZU, RIICHIRO
INOHARA, HIDENORI
IZUMOTO, SHUICHI
NONOMURA, NORIO
YOSHIMINE, TOSHIKI
OKUMURA, MEINOSHIN
MORII, EIICHI
MAEDA, HAJIME
NISHIDA, SUMIYUKI
HOSEN, NAOKI
TSUBOI, AKIHIRO
OKA, YOSHIHIRO
SUGIYAMA, HARUO
author_facet OJI, YUSUKE
TATSUMI, NAOYA
FUKUDA, MARI
NAKATSUKA, SHIN-ICHI
AOYAGI, SAYAKA
HIRATA, ERIKA
NANCHI, ISAMU
FUJIKI, FUMIHIRO
NAKAJIMA, HIROKO
YAMAMOTO, YUMIKO
SHIBATA, SYOHEI
NAKAMURA, MICHIYO
HASEGAWA, KANA
TAKAGI, SAYAKA
FUKUDA, IKUYO
HOSHIKAWA, TOMOKO
MURAKAMI, YUI
MORI, MASAHIDE
INOUE, MASAYOSHI
NAKA, TETSUJI
TOMONAGA, TAKESHI
SHIMIZU, YOSHIFUMI
NAKAGAWA, MASASHI
HASEGAWA, JUNICHI
NEZU, RIICHIRO
INOHARA, HIDENORI
IZUMOTO, SHUICHI
NONOMURA, NORIO
YOSHIMINE, TOSHIKI
OKUMURA, MEINOSHIN
MORII, EIICHI
MAEDA, HAJIME
NISHIDA, SUMIYUKI
HOSEN, NAOKI
TSUBOI, AKIHIRO
OKA, YOSHIHIRO
SUGIYAMA, HARUO
author_sort OJI, YUSUKE
collection PubMed
description Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin’s lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786–794 aa) and EF292 (eEF2 292–300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A(*)24:02- and an HLA-A(*)02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers.
format Online
Article
Text
id pubmed-4027928
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40279282014-05-20 The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers OJI, YUSUKE TATSUMI, NAOYA FUKUDA, MARI NAKATSUKA, SHIN-ICHI AOYAGI, SAYAKA HIRATA, ERIKA NANCHI, ISAMU FUJIKI, FUMIHIRO NAKAJIMA, HIROKO YAMAMOTO, YUMIKO SHIBATA, SYOHEI NAKAMURA, MICHIYO HASEGAWA, KANA TAKAGI, SAYAKA FUKUDA, IKUYO HOSHIKAWA, TOMOKO MURAKAMI, YUI MORI, MASAHIDE INOUE, MASAYOSHI NAKA, TETSUJI TOMONAGA, TAKESHI SHIMIZU, YOSHIFUMI NAKAGAWA, MASASHI HASEGAWA, JUNICHI NEZU, RIICHIRO INOHARA, HIDENORI IZUMOTO, SHUICHI NONOMURA, NORIO YOSHIMINE, TOSHIKI OKUMURA, MEINOSHIN MORII, EIICHI MAEDA, HAJIME NISHIDA, SUMIYUKI HOSEN, NAOKI TSUBOI, AKIHIRO OKA, YOSHIHIRO SUGIYAMA, HARUO Int J Oncol Article Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin’s lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786–794 aa) and EF292 (eEF2 292–300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A(*)24:02- and an HLA-A(*)02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers. D.A. Spandidos 2014-03-04 /pmc/articles/PMC4027928/ /pubmed/24589652 http://dx.doi.org/10.3892/ijo.2014.2318 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Article
OJI, YUSUKE
TATSUMI, NAOYA
FUKUDA, MARI
NAKATSUKA, SHIN-ICHI
AOYAGI, SAYAKA
HIRATA, ERIKA
NANCHI, ISAMU
FUJIKI, FUMIHIRO
NAKAJIMA, HIROKO
YAMAMOTO, YUMIKO
SHIBATA, SYOHEI
NAKAMURA, MICHIYO
HASEGAWA, KANA
TAKAGI, SAYAKA
FUKUDA, IKUYO
HOSHIKAWA, TOMOKO
MURAKAMI, YUI
MORI, MASAHIDE
INOUE, MASAYOSHI
NAKA, TETSUJI
TOMONAGA, TAKESHI
SHIMIZU, YOSHIFUMI
NAKAGAWA, MASASHI
HASEGAWA, JUNICHI
NEZU, RIICHIRO
INOHARA, HIDENORI
IZUMOTO, SHUICHI
NONOMURA, NORIO
YOSHIMINE, TOSHIKI
OKUMURA, MEINOSHIN
MORII, EIICHI
MAEDA, HAJIME
NISHIDA, SUMIYUKI
HOSEN, NAOKI
TSUBOI, AKIHIRO
OKA, YOSHIHIRO
SUGIYAMA, HARUO
The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title_full The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title_fullStr The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title_full_unstemmed The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title_short The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
title_sort translation elongation factor eef2 is a novel tumor-associated antigen overexpressed in various types of cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027928/
https://www.ncbi.nlm.nih.gov/pubmed/24589652
http://dx.doi.org/10.3892/ijo.2014.2318
work_keys_str_mv AT ojiyusuke thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tatsuminaoya thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fukudamari thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakatsukashinichi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT aoyagisayaka thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hirataerika thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nanchiisamu thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fujikifumihiro thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakajimahiroko thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT yamamotoyumiko thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT shibatasyohei thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakamuramichiyo thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hasegawakana thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT takagisayaka thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fukudaikuyo thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hoshikawatomoko thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT murakamiyui thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT morimasahide thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT inouemasayoshi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakatetsuji thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tomonagatakeshi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT shimizuyoshifumi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakagawamasashi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hasegawajunichi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nezuriichiro thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT inoharahidenori thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT izumotoshuichi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nonomuranorio thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT yoshiminetoshiki thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT okumurameinoshin thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT moriieiichi thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT maedahajime thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nishidasumiyuki thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hosennaoki thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tsuboiakihiro thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT okayoshihiro thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT sugiyamaharuo thetranslationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT ojiyusuke translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tatsuminaoya translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fukudamari translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakatsukashinichi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT aoyagisayaka translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hirataerika translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nanchiisamu translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fujikifumihiro translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakajimahiroko translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT yamamotoyumiko translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT shibatasyohei translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakamuramichiyo translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hasegawakana translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT takagisayaka translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT fukudaikuyo translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hoshikawatomoko translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT murakamiyui translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT morimasahide translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT inouemasayoshi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakatetsuji translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tomonagatakeshi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT shimizuyoshifumi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nakagawamasashi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hasegawajunichi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nezuriichiro translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT inoharahidenori translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT izumotoshuichi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nonomuranorio translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT yoshiminetoshiki translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT okumurameinoshin translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT moriieiichi translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT maedahajime translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT nishidasumiyuki translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT hosennaoki translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT tsuboiakihiro translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT okayoshihiro translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers
AT sugiyamaharuo translationelongationfactoreef2isanoveltumorassociatedantigenoverexpressedinvarioustypesofcancers